Dyslipidemia as a risk factor for liver fibrosis progression in a multicentric population with non-alcoholic steatohepatitis
| Autor: | Nashla Hamdan-Pérez, Fátima Higuera-de-la-Tijera, Samantha Cabrera-Palma, Luis A Pérez-Arredondo, Beatriz Barranco-Fragoso, Alfonso Vera-Barajas, Nancy E. Aguilar-Olivos, Alejandro Valencia-Rodríguez, Arturo Panduro, Edgar Coronado-Alejandro, Ana K. Salas-García, Nahum Méndez-Sánchez, Xingshun Qi, Emma Purón-González, Guillermo Cabrera-Álvarez, Heriberto Rodríguez-Hernández, Vania Cruz-Ramón, Oscar Ramírez-Pérez, Carlos Alejandro Cortez-Hernández, E. Cerda-Reyes |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
Adult Liver Cirrhosis Male medicine.medical_specialty Cirrhosis Carcinoma Hepatocellular type 2 diabetes mellitus Population Gastroenterology General Biochemistry Genetics and Molecular Biology 03 medical and health sciences 0302 clinical medicine Fibrosis metabolic syndrome Risk Factors Internal medicine Nonalcoholic fatty liver disease medicine Humans General Pharmacology Toxicology and Pharmaceutics Risk factor education Mexico Aged Dyslipidemias Retrospective Studies education.field_of_study General Immunology and Microbiology business.industry cirrhosis dyslipidemia Liver Neoplasms non-alcoholic fatty liver disease General Medicine Articles Middle Aged medicine.disease 030104 developmental biology Cross-Sectional Studies Diabetes Mellitus Type 2 030211 gastroenterology & hepatology Female Metabolic syndrome Steatohepatitis business Dyslipidemia Research Article |
| Zdroj: | F1000Research |
| ISSN: | 2046-1402 |
| Popis: | Background: Nonalcoholic fatty liver disease (NAFLD) is a serious worldwide health problem, with an estimated global prevalence of 24%; it has a notable relationship with other metabolic disorders, like obesity and type 2 diabetes mellitus (T2DM). Nonalcoholic steatohepatitis (NASH) is one of the most important clinical entities of NAFLD, which is associated with an increased risk of progression to liver cirrhosis and hepatocellular carcinoma (HCC). Mexico is one of the countries with the highest prevalence of metabolic diseases; therefore, we sought to investigate the impact that these clinical entities have in the progression to advanced fibrosis in Mexican patients with NASH. Methods: We performed a multicenter retrospective cross-sectional study, from January 2012 to December 2017. A total of 215 patients with biopsy-proven NASH and fibrosis were enrolled. NASH was diagnosed according NAS score and liver fibrosis was staged by the Kleiner scoring system. For comparing the risk of liver fibrosis progression, we divided our sample into two groups. Those patients with stage F0-F2 liver fibrosis were included in the group with non-significant liver fibrosis (n=178) and those individuals with F3-F4 fibrosis were included in the significant fibrosis group (n=37). We carried out a multivariate analysis to find risk factors associated with liver fibrosis progression. Results: From the 215 patients included, 37 had significant liver fibrosis (F3-4). After logistic regression analysis T2DM (p=0.044), systemic arterial hypertension (p=0.014), cholesterol (p=0.041) and triglycerides (p=0.015) were the main predictor of advanced liver fibrosis. Conclusions: In a Mexican population, dyslipidemia was the most important risk factor associated with advanced liver fibrosis and cirrhosis. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|